Stock Events

Stock Events

Q32 Bio 

$11.99
61
-$0.81-6.33% 20:00 Today
-$0.01-0.06%21:44After hours

Statistics

Day High
12.7
Day Low
11.6
52W High
23.57
52W Low
1.63
Volume
851,282
Avg. Volume
1,132,947
Mkt Cap
356.94M
P/E Ratio
4.03
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.53
-1.13
-0.72
-0.32
Expected EPS
-0.32
Actual EPS
N/A

Financials

55.49%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
53.74MRevenue
29.82MNet Income

Analyst Ratings

38.00Average Price Target
The highest estimate is 66.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QTTB. It's not an investment recommendation.
NVIDIA
7
NVDA
Intel
7
INTC
Realty Income
6
O
Alphabet
6
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is a leader in the development of gene-based therapies using CRISPR/Cas9 technology, directly competing with Homology's gene editing platform.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the gene editing space using CRISPR technology, similar to Homology Medicines, targeting genetic diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in CRISPR-based gene editing, competing in the same space as Homology Medicines for genetic disorder treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing in the genetic disease treatment market.
Regenxbio
RGNX
Mkt Cap637.69M
REGENXBIO is a biotechnology company focusing on the development, commercialization of gene therapies, directly competing with Homology's gene therapy approach.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, through its acquisition of Bamboo Therapeutics and other initiatives, has entered the gene therapy space, making it a competitor in the broader market that Homology Medicines operates in.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisition of Kite Pharma and focus on cell therapies, competes in the advanced therapy medicinal products space, including gene therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals, through its collaboration with CRISPR Therapeutics and focus on treating genetic diseases, competes in the same therapeutic areas as Homology Medicines.

About

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Show more...
CEO
Jodie Pope Morrison
Employees
22
Country
United States
ISIN
US7469641051
WKN
000A4ZZ0Z

Listings

LSE
GB
0T6G.LSE
STU
DE
DB0.STU
XNAS
US
QTTB
MU
DE
35H.MU

0 Comments

Share your thoughts

FAQ

What is Q32 Bio stock price today?▼
The current price of QTTB is $11.99 USD — it has decreased by -6.33% in the past 24 hours. Watch Q32 Bio stock price performance more closely on the chart.
What is Q32 Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Q32 Bio stocks are traded under the ticker QTTB.
Is Q32 Bio stock price growing?▼
QTTB stock has fallen by -20.23% compared to the previous week, the month change is a -25.78% fall, over the last year Q32 Bio has showed a +622.29% increase.
What is Q32 Bio market cap?▼
Today Q32 Bio has the market capitalization of 356.94M
When is the next Q32 Bio earnings date?▼
Q32 Bio is going to release the next earnings report on November 05, 2026.
What were Q32 Bio earnings last quarter?▼
QTTB earnings for the last quarter are -0.44 USD per share, whereas the estimation was -0.46 USD resulting in a +4.34% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Q32 Bio revenue for the last year?▼
Q32 Bio revenue for the last year amounts to 53.74M USD.
What is Q32 Bio net income for the last year?▼
QTTB net income for the last year is 29.82M USD.
How many employees does Q32 Bio have?▼
As of September 04, 2026, the company has 22 employees.
In which sector is Q32 Bio located?▼
Q32 Bio operates in the Health & Wellness sector.
When did Q32 Bio complete a stock split?▼
The last stock split for Q32 Bio was on March 20, 2024 with a ratio of 1:1.
Where is Q32 Bio headquartered?▼
Q32 Bio is headquartered in WALTHAM, United States.